NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma

NEXT STORY
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
PREV STORY
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress

author_avatar
NASDAQ Market News

Industrial Microbiology Market To Be Worth USD 17.71 Billion by 2027| Emergen Research

author_avatar
NASDAQ Market News

Publishing of Orion Corporation’s Interim Report for January-September 2017 on 26 October 2017

ORION CORPORATION     PRESS RELEASE   12 OCTOBER 2017 at 10.30 A.M. EEST Publishing of Orion ...

author_avatar
NASDAQ Market News